Sheedy Connor J, Chowdhury Soham P, Ali Bashir A, Miyamoto Julia, Pang Eric Z, Bacal Julien, Tavasoli Katherine U, Richardson Chris D, Gardner Brooke M
Biomolecular Science and Engineering Program, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.
These authors contributed equally.
bioRxiv. 2024 Dec 13:2024.12.10.627778. doi: 10.1101/2024.12.10.627778.
The PEX1/PEX6 AAA-ATPase is required for the biogenesis and maintenance of peroxisomes. Mutations in and disrupt peroxisomal matrix protein import and are the leading cause of Peroxisome Biogenesis Disorders (PBDs). The most common disease-causing mutation in PEX1 is the PEX1 allele, which results in a reduction of peroxisomal protein import. Here we demonstrate that the homologous yeast mutant, Pex1, reduces the stability of Pex1's active D2 ATPase domain and impairs assembly with Pex6, but can still form an active AAA-ATPase motor. , Pex1 exhibits only a slight defect in peroxisome import. We generated model human PEX1 cell lines and show that PEX1 is rapidly degraded by the proteasome, but that induced overexpression of PEX1 can restore peroxisome import. Additionally, we found that the G843D mutation reduces PEX1's affinity for PEX6, and that impaired assembly is sufficient to induce degradation of PEX1. Lastly, we found that fusing a deubiquitinase to PEX1 significantly hinders its degradation in mammalian cells. Altogether, our findings suggest a novel regulatory mechanism for PEX1/PEX6 hexamer assembly and highlight the potential of protein stabilization as a therapeutic strategy for PBDs arising from the G843D mutation and other PEX1 hypomorphs.
PEX1/PEX6 AAA-ATP酶是过氧化物酶体生物合成和维持所必需的。PEX1和PEX6中的突变会破坏过氧化物酶体基质蛋白的导入,是过氧化物酶体生物合成障碍(PBDs)的主要原因。PEX1中最常见的致病突变是PEX1等位基因,它会导致过氧化物酶体蛋白导入减少。在这里,我们证明,与酵母同源的突变体Pex1会降低Pex1活性D2 ATP酶结构域的稳定性,并损害其与Pex6的组装,但仍能形成有活性的AAA-ATP酶马达。此外,Pex1在过氧化物酶体导入方面仅表现出轻微缺陷。我们构建了人源PEX1模型细胞系,并表明PEX1会被蛋白酶体迅速降解,但诱导PEX1的过表达可以恢复过氧化物酶体的导入。此外,我们发现G843D突变降低了PEX1与PEX6的亲和力,组装受损足以诱导PEX1的降解。最后,我们发现将去泛素酶与PEX1融合会显著阻碍其在哺乳动物细胞中的降解。总之,我们的研究结果提示了一种新的PEX1/PEX6六聚体组装调控机制,并突出了蛋白质稳定化作为治疗由G843D突变及其他PEX1亚效等位基因引起的PBDs的治疗策略的潜力。